Crìa Technologies wins a 2026 W.A. de Vigier Award
What's the deal? Crìa Technologies, a Geneva-area startup that makes high-vacuum insulated containers for transporting sensitive biological materials, has won the 2026 W.A. de Vigier Award — Switzerland's oldest prize for young entrepreneurs. The company, led by chief executive Giancarlo Mattiello, receives CHF 120,000 in seed funding.
Crìa was one of five winners selected from more than 200 applicants. The awards were presented on June 10 at a ceremony in Solothurn. The total prize pool this year reached CHF 700,000.
The startup's core product, Crìa Go, is a shoulder-carriable, cabin-compatible container that uses reusable ice packs instead of dry ice to deliver cryogenic-level performance. The technology was developed at CERNDealroom has a profile for this one. Try Dealroom → and targets a real problem: therapies such as cell and gene treatments, IVF samples, and stem cells require ultra-stable temperatures during transit, yet dry ice is cumbersome and prone to fluctuations that can destroy irreplaceable samples.
Why now? Cell and gene therapies are booming, and the logistics around them haven't kept pace. As more personalised treatments reach patients, the need for reliable cold-chain transport grows sharper — making Crìa's timing apt.
The W.A. de Vigier FoundationDealroom has a profile for this one. Try Dealroom →, now in its 39th year, has distributed CHF 15.6M to over 160 ventures since its founding. Crìa is the only life science winner from Western Switzerland this year, joining peers from Zurich, Bern, and Solothurn.
What could go wrong? CHF 120,000 is a modest sum for a hardware startup tackling regulated medical logistics. Crìa will need significantly more capital to scale manufacturing, win certifications, and build distribution — all areas where deep-tech hardware ventures routinely stumble.
Competition in cold-chain transport is stiff, with established players and well-funded newcomers vying for the same customers. Crìa must prove its CERN-derived technology works not just in the lab but across messy real-world supply chains.
The signal: Crìa Technologies remains at the early stage, according to Dealroom, and the CHF 120,000 prize — while prestigious — underscores how thin the capitalisation layer still is for European deep-tech hardware startups tackling regulated cold-chain logistics. With the global cell and gene therapy market expanding rapidly, the company's CERN-derived vacuum insulation technology addresses a supply-chain bottleneck that is only set to widen, positioning it well for a larger fundraise if it can demonstrate real-world reliability beyond the lab.
Read more: BioAlps
